KRAS and colorectal carcinoma: Since mutated KRAS is resistant to EGFR-targeted mAbs [38], our data that show co-application of cetuximab with 5-FU is effective for both lines may suggest that the effects of cetuximab on cell death are indirectly and may result from the changes of sensitivity of CRC cells to 5-FU.